rosiglitazone has been researched along with triciribine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, J; Liu, L; Liu, Y; Sun, J; Xia, S; Xu, D; Xu, Y; Yang, Z; Zhang, L; Zou, F | 1 |
1 other study(ies) available for rosiglitazone and triciribine
Article | Year |
---|---|
Inhibition of oxidative stress-elicited AKT activation facilitates PPARĪ³ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Glycoproteins; Humans; Liver Neoplasms; Male; Membrane Glycoproteins; Mice; Mice, Nude; NADPH Oxidase 2; NADPH Oxidases; Neoplastic Stem Cells; Oxidative Stress; Peptides; Phenotype; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Ribonucleosides; Rosiglitazone; Thiazolidinediones | 2013 |